Glp 1 Agonist | List of Frontiers open access articles

Original Research

Published on 31 Jul 2025

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants

in Pharmacoepidemiology

Amirah Alhowiti
Hyder Mirghani
Abdulaziz Abdulrahman Qrmli
Amal Abdullah Albalawi
Raneem Abdulrahman Aljohani

Frontiers in Pharmacology

doi 10.3389/fphar.2025.1510554

3,447 views
1 citation

Case Report

Published on 01 Mar 2019

Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism

in Psychopharmacology

Anna Järvinen
Merja K. Laine
Roope Tikkanen
Maija L. Castrén

Frontiers in Psychiatry

doi 10.3389/fpsyt.2019.00097

16,062 views
26 citations

Original Research

Published on 06 Feb 2023

Efficacy of IAPP suppression in mouse and human islets by GLP-1 analogue conjugated antisense oligonucleotide

in Protein Biochemistry for Basic and Applied Sciences

Tatyana Gurlo
Thazha P. Prakash
Zhongying Wang
Maani Archang
Lina Pei
Madeline Rosenberger
Elaine Pirie
Richard G. Lee
Peter C. Butler

Frontiers in Molecular Biosciences

doi 10.3389/fmolb.2023.1096286

4,734 views
6 citations

Original Research

Published on 04 Mar 2021

Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway

in Gastrointestinal and Hepatic Pharmacology

Rui Zhou
Chuman Lin
Yanzhen Cheng
Xiaoyun Zhuo
Qinghua Li
Wen Xu
Liang Zhao
Li Yang

Frontiers in Pharmacology

doi 10.3389/fphar.2020.600175

9,169 views
50 citations

Original Research

Published on 07 Jul 2021

GLP-1-Induced AMPK Activation Inhibits PARP-1 and Promotes LXR-Mediated ABCA1 Expression to Protect Pancreatic β-Cells Against Cholesterol-Induced Toxicity Through Cholesterol Efflux

in Molecular and Cellular Pathology

Rao Li
Xulong Sun
Pengzhou Li
Weizheng Li
Lei Zhao
Liyong Zhu
Shaihong Zhu

Frontiers in Cell and Developmental Biology

doi 10.3389/fcell.2021.646113

8,853 views
23 citations

Original Research

Published on 27 May 2024

Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database

in Gastrointestinal and Hepatic Pharmacology

Khalidah A. Alenzi
Deemah Alsuhaibani
Bader Batarfi
Thamir M. Alshammari

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1364110

15,275 views
34 citations

Articles

Barriers to glucagon-like peptide-1 agonists used for obesity management among the general population in Tabuk City, Saudi Arabia, and their relation to smoking cessation and antidepressants

Beneficial Effects of GLP-1 Agonist in a Male With Compulsive Food-Related Behavior Associated With Autism

Efficacy of IAPP suppression in mouse and human islets by GLP-1 analogue conjugated antisense oligonucleotide

Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway

GLP-1-Induced AMPK Activation Inhibits PARP-1 and Promotes LXR-Mediated ABCA1 Expression to Protect Pancreatic β-Cells Against Cholesterol-Induced Toxicity Through Cholesterol Efflux

Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database